Amgen Europe B.V.
25 products tracked · names used in filings: Amgen Europe B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 29 May 2026🇪🇺 EU approval (EC decision)
Imdylltra (tarlatamab) approved in the EU
Marketing authorisation to Amgen Europe B.V.; Orphan, Additional monitoring · source
Thu 26 Mar 2026🇪🇺 CHMP positive opinion
Imdylltra (tarlatamab): CHMP positive opinion
Amgen Europe B.V.; Orphan, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Kyomarc bevacizumab | Application withdrawn | |
| 🇪🇺 | ABP 710 infliximab | Application withdrawn | |
| 🇪🇺 | Imdylltra tarlatamab | Authorised | 2026-05-29 |
| 🇪🇺 | Tepezza teprotumumab | Authorised | 2025-06-19 |
| 🇪🇺 | Bekemv eculizumab | Authorised | 2023-04-19 |
| 🇪🇺 | Uplizna inebilizumab | Authorised | 2022-04-25 |
| 🇪🇺 | Lumykras sotorasib | Authorised | 2022-01-06 |
| 🇪🇺 | Kanjinti trastuzumab | Authorised | 2018-05-16 |
| 🇪🇺 | Mvasi bevacizumab | Authorised | 2018-01-15 |
| 🇪🇺 | Solymbic adalimumab | Withdrawn | 2017-03-22 |
| 🇪🇺 | Amgevita adalimumab | Authorised | 2017-03-21 |
| 🇪🇺 | Parsabiv etelcalcetide | Authorised | 2016-11-11 |
| 🇪🇺 | Imlygic talimogene laherparepvec | Authorised | 2015-12-16 |
| 🇪🇺 | Blincyto blinatumomab | Authorised | 2015-11-23 |
| 🇪🇺 | Kyprolis carfilzomib | Authorised | 2015-11-19 |
| 🇪🇺 | Repatha evolocumab | Authorised | 2015-07-17 |
| 🇪🇺 | Ristempa pegfilgrastim | Withdrawn | 2015-04-13 |
| 🇪🇺 | Otezla apremilast | Authorised | 2015-01-15 |
| 🇪🇺 | Xgeva denosumab | Authorised | 2011-07-13 |
| 🇪🇺 | Prolia denosumab | Authorised | 2010-05-26 |
| 🇪🇺 | Nplate romiplostim | Authorised | 2009-02-04 |
| 🇪🇺 | Vectibix panitumumab | Authorised | 2007-12-03 |
| 🇪🇺 | Mimpara cinacalcet | Withdrawn | 2004-10-22 |
| 🇪🇺 | Neulasta pegfilgrastim | Authorised | 2002-08-22 |
| 🇪🇺 | Aranesp darbepoetin alfa | Authorised | 2001-06-08 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.